FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway.
Frontiers in bioengineering and biotechnology · Abstract available
All research
COMPOUND RESEARCH
FOXO4-DRI
Follow the papers. Understand the context.
6 papers · 0 trial recordsChecked 18 Sept 2026
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI.
Nature communications · Abstract available
FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation.
Communications biology · Abstract available
FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells.
Experimental gerontology · Abstract available
Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes.
Frontiers in bioengineering and biotechnology · Abstract available
FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice.
Aging · Abstract available
Publications match compound names in their titles. Trial matches use intervention names. An association with a compound is not a finding about its effectiveness. How we select records.